Medical device maker ResMed Inc has appointed Shubhi Khurana as General Manager for India and south Asia, as it makes a major push into the high-growth region.

Subhi Khurana, a former general manager of Capsugel India region (now Lonza), will oversee business operations, including setting strategic priorities and go-to-market strategy, ResMed said.

The $6.8 billion company focuses on the sleep and related respiratory care markets, which it believes are untapped opportunities around the world. The company aims to expand into high-growth areas including China, India, Eastern Europe, Brazil and south-east Asia.

“In India, these diseases are highly under-diagnosed due to low awareness amongst both doctors and the general community. Given the link between these diseases, and other chronic diseases like diabetes, hypertension, stroke, cognitive disorders and cancer, it is critical we continue to educate and treat people with these conditions,” said Justin Leong, ResMed president of Asia growth markets.

The San Diego-based group recently posted a 12 per cent climb in revenue for the March quarter to $US662.2 million ($946.3 million), underpinned by demand for masks and devices to treat sleep apnoea in international markets and contributions from its recently acquired software-as-a-service companies.

Ms Khurana said research on the effects of sleep apnoea, characterised by snoring and interrupted sleep, and COPD is only a few decades old, and therefore the potential to affect lives and health of sufferers through ResMed’s offerings is “a great opportunity”.

Ms Khurana has more than two decades of experience in the pharmaceutical, healthcare and medical technology industries in various leadership roles. Before her role at Capsugel, she worked at Baxter and Baxalta, building their critical care, rare diseases and surgical kits business.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.